{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:01:53Z","timestamp":1776733313262,"version":"3.51.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>In March 2022, a 58-year-old man was admitted to the local hospital for nausea and vomiting. His blood routine indicated that he had leukocytosis and anemia. The patient was diagnosed with acute myeloid leukemia (AML)-M5b accompanied by <jats:italic>DNMT3A, FLT3-TKD<\/jats:italic>, and <jats:italic>IDH2<\/jats:italic> mutations, chest CT revealed pulmonary tuberculosis (TB). Acid-fast bacillus (AFB) was detected in sputum. The patient then received anti-TB treatment with isoniazid + rifampicin + pyrazinamide + ethambutol. On April 8, he was transferred to our hospital's Hematology Department after three consecutive negative sputum smears. He was administered the VA (Venetoclax + Azacytidine) regimen of anti-leukemia treatment and also received levofloxacin + isohydrazide + pyrazinamide + ethambutol anti-TB treatment. After one course of VA therapy, there was no remission in the bone marrow. Therefore, the patient received the HVA (Homeharringtonine + Venetoclax + Azacytidine) regimen of anti-leukemia treatment. On May 25, the bone marrow smear revealed that the original mononuclear cells were 1%. Moreover, bone marrow flow cytometry revealed the absence of any abnormal cells. mNGS showed DNMT3A (mutation rate 44.7%), but no mutations were detected in FLT3-TKD and IDH2. The patient then received the HVA regimen three consecutive times, resulting in complete remission. Repeated chest CT examinations revealed progressive regression of pulmonary TB foci, no AFB was detected in the sputum. This AML patient with DNMT3A, FLT3-TKD, and IDH2 mutations and active TB is difficult to treat. It is very necessary for him to administer prompt anti-leukemia treatment under the premise of active anti-TB treatment. The HVA regimen is effective for this patient.<\/jats:p>","DOI":"10.3389\/fmed.2023.1180757","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T04:39:01Z","timestamp":1686631141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A case report of complete remission of acute myeloid leukemia combined with DNMT3A, FLT3-TKD, and IDH2 gene mutations and active pulmonary tuberculosis treated with homeharringtonine + venetoclax + azacytidine"],"prefix":"10.3389","volume":"10","author":[{"given":"Lin","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-014-0074-4","article-title":"Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations","volume":"7","author":"Loghavi","year":"2014","journal-title":"J Hematol Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood.2019003339","article-title":"Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis","volume":"135","author":"Bezerra","year":"2020","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.19746\/j.cnki.issn.1009-2137.2019.05.014","article-title":"Coexisting mutations in IDH1\/2-mutated acute myeloid leukemia","volume":"27","author":"Jia","year":"2019","journal-title":"J Exp Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-16-2628","article-title":"Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"23","author":"Xu","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3324\/haematol.2018.208835","article-title":"Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1\/TET1\/5hmC","volume":"105","author":"Li","year":"2020","journal-title":"Haematologica."},{"key":"B7","unstructured":"Global tuberculosis report 20212021"},{"key":"B8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.16718\/j.1009-7708.2019.03.003","article-title":"Clinical cases of tuberculosis in leukemia patients in China: an analysis","volume":"19","author":"Li","year":"2019","journal-title":"Chinese J Infect Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3760\/cma.j.issn.0253-2727.2021.08.001","article-title":"Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) 2021","volume":"42","year":"2021","journal-title":"Chinese J Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Mali","year":"2021","journal-title":"Haematologica."},{"key":"B13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3390\/pathogens11050492","article-title":"Diverse cell death mechanisms are simultaneously activated in macrophages infected by virulent mycobacterium tuberculosis","volume":"11","author":"Ramon-Luing","year":"2022","journal-title":"Pathogens (Basel, Switzerland)."},{"key":"B14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.21037\/atm-22-1459","article-title":"Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms","volume":"10","author":"Yuan","year":"2022","journal-title":"Ann Transl Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-138676","article-title":"Combination of homoharringtonine with venetoclax and azacitidine excerts better treatment response in relapsed\/refractory acute myeloid leukemia","volume":"136","author":"Yu","year":"2020","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1073\/pnas.1703476114","article-title":"Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement","volume":"114","author":"Dai","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1038\/s41467-022-33410-w","article-title":"Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun."},{"key":"B18","volume-title":"Phase 3, multicenter, open-label study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 mutated (FLT3mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy","author":"Wang","year":"2020"},{"key":"B19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-91439-8_9","article-title":"Enasidenib","volume":"212","author":"Kr\u00e4mer","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"B22","first-page":"290","article-title":"Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country","volume":"11","author":"Mirgh","year":"2021","journal-title":"Am J Blood Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"11901","DOI":"10.1038\/s41598-019-48395-8","article-title":"The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse","volume":"9","author":"Shu","year":"2019","journal-title":"Sci Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3760\/cma.j.issn.0253-2727.2013.12.020","article-title":"Clinical research progress of hematologicalmalignancies complicated with active tuberculosis","volume":"34","author":"Li","year":"2013","journal-title":"Chinese J Hematol."},{"key":"B25","unstructured":"2021"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1180757\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T04:39:09Z","timestamp":1686631149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1180757\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":25,"alternative-id":["10.3389\/fmed.2023.1180757"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1180757","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"article-number":"1180757"}}